Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00311584 · ClinicalTrials.gov registry record · Phase 2
Irinotecan and Temozolomide in Treating Young Patients With Recurrent Neuroblastoma
A Phase 2 study, sponsored by Children's Oncology Group.
- Completed
- Registry status
- Phase 2
- Development phase
- 59
- Enrollment target
NCT00311584 is a Phase 2 study that has completed, run by Children's Oncology Group. The registered enrollment target is 59 participants.
The verdict
NCT00311584, a Phase 2 study, has completed, sponsored by Children's Oncology Group.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 59 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy, such as irinotecan and temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving irinotecan together with temozolomide works in treating young patients with recurrent neuroblastoma.
Interventions
- DRUG temozolomide
- DRUG irinotecan hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 59 participants |
| Start Date | 2006-04 |
| Est. Completion | 2013-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00311584
The ClinicalTrials.gov registry entry for NCT00311584 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 59 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Children's Oncology Group, which has 342 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which temozolomide is the first listed.
NCT00311584 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00311584 about?
NCT00311584 is a clinical study titled "Irinotecan and Temozolomide in Treating Young Patients With Recurrent Neuroblastoma". RATIONALE: Drugs used in chemotherapy, such as irinotecan and temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. PURPOSE: This phase II...
What is the current status of trial NCT00311584?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 59 participants. The study started on 2006-04. Estimated completion is 2013-12.
What interventions are being tested in trial NCT00311584?
The interventions under investigation include: temozolomide (DRUG), irinotecan hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00311584?
This trial is sponsored by Children's Oncology Group, which has 342 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.